Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent-Reform Risks Remain For Device Firms In Lawmaker Efforts

This article was originally published in The Gray Sheet

Executive Summary

With the legislative calendar winding down, the chances for passage of a patent bill in 2014 are waning, but lawmaker efforts targeting patent trolls should not be ignored because they hold serious potential risks for small device firms, an attorney says.

You may also be interested in...



Senate Bill Takes Targeted, MedTech-Supported Approach To Patent Trolls

The STRONG Patents Act includes multiple provisions that device and biotech firms say would strengthen the patent system and appropriately take a targeted approach to patent trolls. But the tech industry favors stronger measures to fight trolls that device companies say would weaken the overall patent system.

Senate Bill Takes Targeted, MedTech-Supported Approach To Patent Trolls

The STRONG Patents Act, introduced this week, includes multiple provisions that device and biotech firms say would strengthen the patent system and appropriately take a targeted approach to patent trolls. But the tech industry favors stronger measures to fight trolls that device companies say would weaken the overall patent system.

J&J Lawyer Considered To Lead U.S. Patent Office

Rumors circulating in the patent community suggest that President Obama plans to nominate Philip Johnson, J&J’s chief intellectual property counsel, to the post of Under Secretary of Commerce for IP and director of the Patent and Trademark Office.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel